{"id":56082,"date":"2026-02-02T22:34:22","date_gmt":"2026-02-02T14:34:22","guid":{"rendered":"https:\/\/flcube.com\/?p=56082"},"modified":"2026-02-02T22:34:24","modified_gmt":"2026-02-02T14:34:24","slug":"nhsa-targets-nrdl-fund-supervision-in-2026-crackdown","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56082","title":{"rendered":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>China\u2019s National Healthcare Security Administration (NHSA)<\/strong> this week issued the <strong>&#8220;Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026&#8221;<\/strong>, extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a &#8220;Three\u2011Line Defense&#8221; system to curb irregular claims and safeguard the <strong>\u00a5300\u202fbillion<\/strong> (~US$42\u202fbillion) NRDL budget.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-inspection-focus-areas-amp-risk-criteria\">Inspection Focus Areas &amp; Risk Criteria<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Target Category<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>High\u2011Risk Regions<\/strong><\/td><td>Areas with operational risks, abnormal hospitalization rates, unusual payment ratios, or inadequate prior rectification<\/td><\/tr><tr><td><strong>High\u2011Volume Institutions<\/strong><\/td><td>Designated hospitals with heavy fund usage<\/td><\/tr><tr><td><strong>Data\u2011Driven Leads<\/strong><\/td><td>Tip\u2011offs and big\u2011data screenings revealing concentrated problematic cases<\/td><\/tr><tr><td><strong>Key Specialties<\/strong><\/td><td>Orthopedics, oncology, medical examination\/testing, ophthalmology, dentistry, general surgery, neurology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-three-line-defense-system-amp-implementation-targets\">Three\u2011Line Defense System &amp; Implementation Targets<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Defense Layer<\/th><th>Function<\/th><th>2026 Goal<\/th><\/tr><\/thead><tbody><tr><td><strong>Pre\u2011transaction<\/strong><\/td><td>Reminders at healthcare institutions before claims<\/td><td>&gt;70% access rate among designated institutions<\/td><\/tr><tr><td><strong>Mid\u2011process<\/strong><\/td><td>Reviews during claim handling<\/td><td>Real\u2011time flagging and interception<\/td><\/tr><tr><td><strong>Post\u2011transaction<\/strong><\/td><td>Administrative supervision and audits<\/td><td>Comprehensive retrospective analysis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharma Industry:<\/strong> Enhanced scrutiny may delay NRDL reimbursement for drugs in targeted specialties; companies must ensure robust clinical and economic evidence<\/li>\n\n\n\n<li><strong>Hospital Sector:<\/strong> High\u2011volume institutions face increased compliance costs; digital claim management systems will become essential<\/li>\n\n\n\n<li><strong>Technology Vendors:<\/strong> Demand for AI\u2011driven pre\u2011transaction reminder systems and big\u2011data screening tools to surge, creating <strong>\u00a55\u201310\u202fbillion<\/strong> : market opportunity<\/li>\n\n\n\n<li><strong>Budget Protection:<\/strong> NRDL fund supervision critical as list expands; 2026 budget growth capped at <strong>7%<\/strong>, making efficiency gains imperative<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Provincial pilot programs to launch <strong>Q2\u202f2026<\/strong>; national audit results expected by <strong>Q4\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding policy implementation timelines, market impacts, and compliance costs associated with NHSA\u2019s 2026 NRDL supervision measures. Actual outcomes may differ due to regional enforcement variations and industry adaptation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2019s National Healthcare Security Administration (NHSA) this week issued the &#8220;Notice on Further Enhancing the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[67],"class_list":["post-56082","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-nhsa-prev-smia"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHSA Targets NRDL Fund Supervision in 2026 Crackdown - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) this week issued the &quot;Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026&quot;, extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a &quot;Three\u2011Line Defense&quot; system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56082\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHSA Targets NRDL Fund Supervision in 2026 Crackdown\" \/>\n<meta property=\"og:description\" content=\"China\u2019s National Healthcare Security Administration (NHSA) this week issued the &quot;Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026&quot;, extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a &quot;Three\u2011Line Defense&quot; system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56082\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-02T14:34:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-02T14:34:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHSA Targets NRDL Fund Supervision in 2026 Crackdown\",\"datePublished\":\"2026-02-02T14:34:22+00:00\",\"dateModified\":\"2026-02-02T14:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NHSA (prev. SMIA)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56082#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56082\",\"name\":\"NHSA Targets NRDL Fund Supervision in 2026 Crackdown - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-02T14:34:22+00:00\",\"dateModified\":\"2026-02-02T14:34:24+00:00\",\"description\":\"China\u2019s National Healthcare Security Administration (NHSA) this week issued the \\\"Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026\\\", extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a \\\"Three\u2011Line Defense\\\" system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56082\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56082#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHSA Targets NRDL Fund Supervision in 2026 Crackdown\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s National Healthcare Security Administration (NHSA) this week issued the \"Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026\", extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a \"Three\u2011Line Defense\" system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56082","og_locale":"en_US","og_type":"article","og_title":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown","og_description":"China\u2019s National Healthcare Security Administration (NHSA) this week issued the \"Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026\", extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a \"Three\u2011Line Defense\" system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.","og_url":"https:\/\/flcube.com\/?p=56082","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-02T14:34:22+00:00","article_modified_time":"2026-02-02T14:34:24+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56082#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56082"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown","datePublished":"2026-02-02T14:34:22+00:00","dateModified":"2026-02-02T14:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56082"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NHSA (prev. SMIA)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56082#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56082","url":"https:\/\/flcube.com\/?p=56082","name":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-02T14:34:22+00:00","dateModified":"2026-02-02T14:34:24+00:00","description":"China\u2019s National Healthcare Security Administration (NHSA) this week issued the \"Notice on Further Enhancing the Supervision of National Reimbursement Drug List (NRDL) Funds in 2026\", extending the 2025 special campaign against fund misuse. The initiative will intensify spot\u2011check inspections and accelerate deployment of a \"Three\u2011Line Defense\" system to curb irregular claims and safeguard the \u00a5300\u202fbillion (~US$42\u202fbillion) NRDL budget.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56082#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56082"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56082#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHSA Targets NRDL Fund Supervision in 2026 Crackdown"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56082"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56082\/revisions"}],"predecessor-version":[{"id":56083,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56082\/revisions\/56083"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}